Lesson plan
Lu 29-252
Lu 29-252 is a selective sigma σ 2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed. It reached the preclinical stage of development prior to the discontinuation of its development. The drug was under development by Lundbeck.
Article summary
Lu 29-252 is a selective sigma σ 2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed. It reached the preclinical stage of development prior to the discontinuation of its development. The drug was under development by Lundbeck.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.